Check this out guys--Spoke to Noelle for a long time,and the most important part of the conversation to relate to you is that the company is aware that the news about the Her2 is misinterpreted and the company did not cann the trial because of the Data. They don`t even have the Efficacy data yet,which was the secondary end point,the primary end point was safety,and it was the same as all of Adxs`s stuff so far,safe. When they get the Efficacy data they`ll PR it,and they`ll maybe then explain why they dropped it,which is exactly why Myself and others here thought. It`s far off from a win,it`s a large cash burn,and the company wants to focus it`s reserves on what it thinks it can get across the goal line in the shortest time,with the least amount of expenditures,so that would ease the need for dilution. By the way she said she spoke to all of our large holders and none sold in this hit. She said she had the Data on sales and it was mostly retail. Would`nt you know it,tutes like Adage love to get rid of retail and have only tutes controlling a stock like ours,especially when the good news comes,so they can control the big move up by not selling until it bids a certain amount..IMO,the tutes let this happen to get rid of as much retail as they can,mainly because they scare the easiest. Think about it. With this knowledge retail from here should be buying right at the bell tomorrow,with longs who understand what just took place. BUY BUY BUY. The company has a plan,and it`s to be in a position of strength to make the best deals possible going forward. They`re gonna send a message to our potential partners that we saw what Kite got,and we have more,so we`re submitting to the EU for Axal on our own..That`s if some partner does`nt pay up big,,the opposite of all of Dan`s deals,so Lombardo is gonna have to play hard ball here,,old school is what he is.
